PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Ann: PAR to present at NWR Healthcare Conference, page-33

  1. 95 Posts.
    lightbulb Created with Sketch. 6
    A Type C FDA meeting led to a Type D meeting, which now requires a "complete (full) response." Mozz, given these safety concerns, would you kindly share how you know this is not a partial or full clinical hold? (i.e., who provided the information?) Thanks, Mate.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.